(MedPage Today) — Adding the dual checkpoint inhibitor regimen of ipilimumab (Yervoy) and nivolumab (Opdivo) to percutaneous hepatic perfusion significantly reduced the risk of disease progression or death in metastatic uveal melanoma, a single…
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/120183
Author :
Publish date : 2026-03-07 15:00:00
Copyright for syndicated content belongs to the linked Source.
